Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd.
Your view on PIQ.AX
Overview
What the company does, where it operates, and who runs it.
About Proteomics International Laboratories Ltd.
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
- CEO
- David N. Morris
- Headquarters
- Harry Perkins Institute of Medical Research, Nedlands, WA, AU
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
- CEO
- David N. Morris
- Headquarters
- Harry Perkins Institute of Medical Research, Nedlands, WA, AU
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD).
The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment.
It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for type 1 diabetes, diabetic retinopathy, and diabetic neuropathy; Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease; Plant Dieback, that is under development phase for phytophthora dieback; Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy; and Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy.
The company also offers analytical services, such as specialist contract research focusing on biomarker discovery, biosimilars quality control, and pharmacokinetic testing for clinical trials.
It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre. Proteomics International Laboratories Ltd was founded in 2001 and is based in Perth, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Proteomics International Laboratories Ltd.. Starting points for Proteomics International Laboratories Ltd.: EPS -AUD 0.07, beta -0.38 — an Medical - Care Facilities name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Proteomics International Laboratories Ltd.. Proteomics International Laboratories Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Proteomics International Laboratories Ltd.. Trailing twelve-month EPS for Proteomics International Laboratories Ltd. stands at -AUD 0.07. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterSep 2025 | Next quarterDec 2025 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | AUD 0.00 | AUD 0.00 | −AUD 0.04 | AUD 0.00 |
| Lowest estimate | AUD 0.00 | AUD 0.00 | −AUD 0.04 | AUD 0.00 |
| Highest estimate | AUD 0.00 | AUD 0.00 | −AUD 0.04 | AUD 0.00 |
| Number of analysts | 0 | 0 | 1 | 0 |
| A year ago | — | — | −AUD 0.05 | — |
| Growth vs a year ago | — | — | +25.1% | — |
Revenue estimates
| Total | This quarterSep 2025 | Next quarterDec 2025 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | AUD 122430.00 | AUD 357440.00 | AUD 5.90M | AUD 113.30M |
| Lowest estimate | AUD 122430.00 | AUD 357440.00 | AUD 5.90M | AUD 113.30M |
| Highest estimate | AUD 122430.00 | AUD 357440.00 | AUD 5.90M | AUD 113.30M |
| Number of analysts | 1 | 1 | 1 | 1 |
| A year ago | — | — | AUD 278015.00 | — |
| Growth vs a year ago | — | — | +2022.2% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Proteomics International Laboratories Ltd.. Proteomics International Laboratories Ltd. has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| ADO.AXAnteoTech Limited | Basic Materials | Chemicals - Specialty | — | ||
| AGN.AXArgenica Therapeutics Ltd | Healthcare | Biotechnology | — | ||
| ATX.AXAmplia Therapeutics Limited | Healthcare | Biotechnology | — | ||
| CSX.AXCleanSpace Holdings Limited | Healthcare | Medical - Devices | — | ||
| CYP.AXCynata Therapeutics Limited | Healthcare | Biotechnology | — | ||
| DOC.AXDoctor Care Anywhere Group PLC | Healthcare | Medical - Healthcare Information Services | — | ||
| NOX.AXNoxopharm Limited | Healthcare | Biotechnology | — | ||
| NSB.AXNeuroScientific Biopharmaceuticals Limited | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| ETAOFETAO International Co., Ltd. | Healthcare | OTC | $2,049 | ||
| EUDAEUDA Health Holdings Limited | Healthcare | NASDAQ | $45.0M | ||
| EUDAWEUDA Health Holdings Limited | Healthcare | NASDAQ | $635,166 | ||
| EVGRFChina Evergrande New Energy Vehicle Group Limited | Healthcare | OTC | $11.9M | ||
| EXE.TOExtendicare Inc. | Healthcare | TSX | $2.7B | ||
| EXETFExtendicare Inc. | Healthcare | OTC | $1.7B | ||
| FCGDFirst Colombia Gold Corp. | Healthcare | OTC | $483,789 | ||
| FCHSFirst Choice Healthcare Solutions, Inc. | Healthcare | OTC | $131,833 | ||
| FMCQFFresenius Medical Care AG & Co. KGaA | Healthcare | OTC | $14.3B | ||
| FMSFresenius Medical Care AG & Co. KGaA | Healthcare | NYSE | $11.3B | ||
| FOXOFOXO Technologies Inc. | Healthcare | OTC | $8,997 | ||
| FPCGFirst Physicians Capital Group, Inc. | Healthcare | OTC | $10.1M | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Proteomics International Laboratories Ltd.. Coverage tracks Proteomics International Laboratories Ltd. within Medical - Care Facilities (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Proteomics International Laboratories Ltd.